2614 PUBLICATIONS
ANNÉE
JOURNAL
PREMIER AUTEUR
TITRE
ANNÉE2022
JOURNALScientific reports
PREMIER AUTEURNguekeu-Zebaze L
TITREPARP3 supervises G9a-mediated repression of adhesion and hypoxia-responsive genes in glioblastoma cells.
ANNÉE2022
JOURNALCells
PREMIER AUTEURDe Azevedo J
TITREThe EXTREME Regimen Associating Cetuximab and Cisplatin Favors Head and Neck Cancer Cell Death and Immunogenicity with the Induction of an Anti-Cancer Immune Response.
ANNÉE2022
JOURNALOncoimmunology
PREMIER AUTEURBarnestein R
TITREImmunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness.
ANNÉE2022
JOURNALAmerican journal of physiology. Cell physiology
PREMIER AUTEURMallard J
TITREDevelopment of skeletal muscle atrophy and intermuscular adipose tissue in early breast cancer patients treated with chemotherapy.
ANNÉE2022
JOURNALDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
PREMIER AUTEURBrugel M
TITREPesticides and pancreatic adenocarcinoma: A transversal epidemiological, environmental and mechanistic narrative review.
ANNÉE2022
JOURNALSurgery
PREMIER AUTEURKhellaf L
TITREThe desmoplastic growth pattern is associated with second-stage completion and longer survival in 2-stage hepatectomy for colorectal cancer liver metastases.
ANNÉE2022
JOURNALChemico-biological interactions
PREMIER AUTEURMcCartin C
TITREAn N-heterocyclic carbene iridium(III) complex as a potent anti-cancer stem cell therapeutic.
ANNÉE2022
JOURNALEuropean journal of cancer (Oxford, England : 1990)
PREMIER AUTEURLepage C
TITRELanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD study.
ANNÉE2022
JOURNALJournal of clinical oncology : official journal of the American Society of Clinical Oncology
PREMIER AUTEURAdotévi O
TITRESafety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based Vaccine in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study.
ANNÉE2022
JOURNALCells
PREMIER AUTEURFonderflick L
TITREThe ATG8 Family Proteins GABARAP and GABARAPL1 Target Antigen to Dendritic Cells to Prime CD4 and CD8 T Cells.

Retrouvez aussi

Personnes
Equipes
Plateformes
Unités de recherche, établissements
Projets de recherche
Publications scientifiques